Novartis Touts Ligelizumab As Xolair Successor In CSU

Filing Planned For 2021

Novartis and Roche's Xolair was approved as a treatment for hives in 2014 and has transformed treatment for patients with severe symptoms. New data on the former's new IgE inhibitor suggest that a more effective drug could be on the way.

Dog_Podium
Novartis hopes ligelizumab will be top dog for CSU • Source: Shutterstock

Novartis AG is highlighting the advantages of its new chronic spontaneous urticaria (CSU) treatment ligelizumab over the current standard of care Xolair which the firm markets with Roche for the distressing condition that causes red, itchy and sometimes painful hives on the skin.

Like Xolair (omalizumab), ligelizumab is an immunoglobulin E inhibitor but Novartis has pointed to new mechanistic data published in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category